Zydus Lifesciences outlines US NDA submissions, strong FY26 India Formulations, and strategic growth moves
Investor Presentation
Business Overview
- Diversified global life-sciences company spanning India formulations, biosimilars, vaccines, consumer wellness, and MedTech.
- FY26 revenue US$3 bn+, EBITDA US$959 mn, R&D spend US$257 mn.
- India Formulations revenue FY26 INR 65,740 mn.
- NDA submissions and acquisitions anchor growth: Saroglitazar Magnesium; Rolvedon; Amplitude Surgical.
- Forecasted expansion through biosimilars, vaccines, and international markets.
Key Operational Highlights
- Saroglitazar Magnesium NDA submitted in Q1 FY27; US Priority Review.
- NDA3 expected approval by Q4 FY27.
- Tishtha: first Nivolumab biosimilar launched in India.
- Amplitude Surgical to function as MedTech platform; Andy robotic solution CE-marked.
- LiqMeds: out-licensed portfolio; UK facility; 14 US filings; 10 approvals; 7 launches.
- Vaccines portfolio: 16 vaccines with Indian approvals; WHO PQ progress.
- International markets growth; biosimilars and specialty therapies focus.
- US generics: 30-35 ANDAs filed annually; 14 USFDA filings; 10 approvals; 7 launches.
Financial Performance
- Group FY26 revenue US$3 bn+; EBITDA US$959 mn.
- FY26 India Formulations revenue INR 65,740 mn.
- FY26 R&D intensity about 8.4% of revenue.
Capital Structure & Liquidity
- No material capital structure changes disclosed in this update.
Strategic Priorities & Outlook
- Monetize diverse pipeline; expand international markets; grow biosimilars, vaccines, and MedTech.
- Expand partnerships, in-licensing, and acquisitions to accelerate growth.
- Invest in R&D and capacity to support global launches and complex therapies.
Risks & Mitigation
- Regulatory approval timelines (US) pose execution risk; mitigated by pre-launch capabilities and diversified portfolio.
- Geographic diversification reduces concentration risk across markets.
Governance & Leadership
- Pankaj Ramanbhai Patel – Non-Executive Chairman; extensive pharma experience.
- Dr. Sharvil Pankajbhai Patel – Managing Director.
- Independent directors reinforce governance framework and board oversight.